Compare Amphastar Pharmaceuticals Inc (AMPH) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Gold Fields Limited — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Gold Fields Limited trades at $40.34 (market cap $36.72B). The key difference: Gold Fields Limited is far larger — about 42.5× Amphastar Pharmaceuticals Inc's market cap, and Gold Fields Limited pays a 5.64% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | GFI | |
|---|---|---|
Market Cap | $863.95M | $36.72B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $61.52 |
52-Week Low | $16.87 | $29.31 |
Enterprise Value | $1.26B | $38.16B |
Dividend Yield | — | 5.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Gold Fields (GFI) trades at $40.82, up 9.32% in 24 hours, reflecting strong momentum near recent highs. The stock shows a bullish technical signal with moving averages supporting upward trends, though RSI levels indicate potential overbought conditions. Fundamentally, GFI exhibits robust profitability with a 40.76% net income margin and attractive valuation metrics, including a P/E of 10.36. Recent earnings have been mixed, with a Q1 2025 beat but subsequent misses, while 2025 revenue is projected to surge to $8.8B. Institutional interest is evident with Allspring Global increasing its stake by 62.3% in Q1 2026 (SEC filing, 2026-07-18).
The outlook for GFI is positive, driven by strong gold prices and operational growth, with a consensus price target of $52.00 offering ~27% upside. Risks include cost inflation, geopolitical factors affecting mining operations, and volatile cash flows from heavy investing activities. Analyst sentiment is cautiously optimistic with 44% buy ratings, but investors should monitor execution on earnings targets and debt levels, which rose to 25.01% of assets in 2024.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
